Both type I and type II PRMTs generate monomethylarginine (mMA) as an intermediate; type I PRMTs further catalyze the formation of asymmetric dimethylarginine (aDMA), and type II PRMTs catalyze the generation of symmetric dimethylarginine (sDMA).32 MTA was found to be favorable to the inhibition of PRMT5 activity.16,17,19 Here, we showed that various MTAP-deleted RCC cells exhibit a reduction in sDMA levels. The gene discussed is PRMT5; the disease is renal cell carcinoma.